Alternate Dosing Schedules for Topotecan in the Treatment of Recurrent Ovarian Cancer

Alternate Dosing Schedules for Topotecan in the Treatment of Recurrent Ovarian Cancer Robert Morris, Adnan Munkarah Oncologist 2002; 7(Suppl 5): 29-35 Author Information and Disclosures Target Audience: Physicians who wish to advance their current knowledge of clinical cancer medicine in clinical pharmacology and are involved in providing patient care in a cancer care environment. Method of Physician Participation: Read course materials, complete course quiz and evaluation form (optional). Learning Objectives After completing this course, the reader should be able to: Identify the rationale for exploring alternative dosing schedules for topotecan. Identify which alternative schedules are being explored and have the most promise. Identify the tolerance and antitumor activity of alternative dosing regimens for topotecan. The NIH/FAES designates this educational activity for a maximum of 1 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

CME Activity Information Accreditation CME Instructions For Credit Privacy Statement Hardware/Software Requirements Release Date: Sept. 24, 2002 Most Recent Review: June 10, 2005* Most Recent Update: Sept. 24, 2002 Date Credit Expires: Apr. 10, 2007 Time to Complete: 1 hour Medium: Internet Online *Click here to learn more about our review process.

Click Here to return to the complete course listing of Current Perspectives in the Treatment of Ovarian Cancer: An Update on the Role of Topotecan